Sanofi to grow sales force over 10% in 2005

Share this article:
Sanofi-Aventis will likely grow its U.S. sales force by upwards of 10 percent in 2005, according to executive vice president, pharmaceutical operations Hanspeter Spek, while advertising and other promotional spend will grow by a far smaller percentage.
Spek tempered his comments, made during a March 21 presentation of R&D news in New York, with a bleak assessment of the sales force arms race, noting the stare-down between rivals Pfizer and GlaxoSmithKline over who would begin making reductions first. But Spek said Sanofi-Aventis would need to expand some specialty field forces – notably CNS – to keep up with a raft of launches expected in 2005 and 2006.
At the end of 2004, the company confirmed it was cutting around 700 global sales and marketing positions at its U.S. headquarters in Bridgewater, N.J. The posts, for Aventis brands, are being moved to the company's Paris headquarters.
Senior vice president and CFO Jean Claude Leroy said the company will increase research and development expenditures to 15.6 percent of sales, or ˆ4 billion, in 2005, and said Sanofi-Aventis has 48 molecules in late stage development, with 10 compounds slated to show results in Phase II-B or III clinical trials this year.
Asked his views on DTC advertising, Spek said "The industry has to be more careful on topics and language," but said he is comfortable with the company's consumer advertising, citing Ambien ads as an example of responsible advertising. Other Sanofi products heavily advertised in the U.S. include Allegra and Plavix, a co-promote with Bristol-Myers Squibb.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...